0112 Sanofi Biond
BioCentury & Getty Images


Sanofi joins the myeloid checkpoint movement with Biond deal

Jan 12, 2021 | 10:16 PM GMT

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2. 

The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and over

Read the full 562 word article

How to gain access

Continue reading with a
two-week free trial.